<!DOCTYPE article
 PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="preprint"><?all-math-mml yes?><?use-mml?><?origin ukpmcpa?><front><journal-meta><journal-id journal-id-type="nlm-ta">bioRxiv</journal-id><journal-title-group><journal-title>bioRxiv : the preprint server for biology</journal-title></journal-title-group><issn pub-type="ppub"/></journal-meta><article-meta><article-id pub-id-type="manuscript">EMS161000</article-id><article-id pub-id-type="doi">10.1101/2021.12.04.471207</article-id><article-id pub-id-type="archive">PPR428825</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group><subj-group subj-group-type="europepmc-category"><subject>Covid-19</subject></subj-group></article-categories><title-group><article-title>HLA<sub>nc</sub>Pred: A method for predicting promiscuous non-classical HLA binding sites</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0400-2084</contrib-id><name><surname>Dhall</surname><given-names>Anjali</given-names></name><email>anjalid@iiitd.ac.in</email></contrib><contrib contrib-type="author" equal-contrib="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1358-292X</contrib-id><name><surname>Patiyal</surname><given-names>Sumeet</given-names></name><email>sumeetp@iiitd.ac.in</email></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8902-2876</contrib-id><name><surname>Raghava</surname><given-names>Gajendra P. S.</given-names></name><xref ref-type="corresp" rid="CR1">*</xref></contrib><aff id="A1">Department of Computational Biology, Indraprastha Institute of Information Technology, Okhla Phase 3, New Delhi-110020, India</aff></contrib-group><author-notes><corresp id="CR1"><label>*</label><bold>Corresponding Author</bold>, Prof. Gajendra P. S. Raghava, Head and Professor, Department of Computational Biology, Indraprastha Institute of Information Technology, Delhi, Okhla Industrial Estate, Phase III, (Near Govind Puri Metro Station), New Delhi, India – 110020 Office: A-302 (R&amp;D Block), Phone: 011-26907444, <email>raghava@iiitd.ac.in</email>, Website: <ext-link ext-link-type="uri" xlink:href="http://webs.iiitd.edu.in/raghava/">http://webs.iiitd.edu.in/raghava/</ext-link></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>18</day><month>01</month><year>2023</year></pub-date><pub-date pub-type="preprint"><day>06</day><month>12</month><year>2021</year></pub-date><permissions><ali:free_to_read/><license><ali:license_ref>https://europepmc.org/downloads/openaccess</ali:license_ref><license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p></license></permissions><abstract><p id="P1">In the last two decades, ample of methods have been developed to predict the classical HLA binders in an antigen. In contrast, limited attempts have been made to develop methods for predicting binders for non-classical HLA; due to the scarcity of sufficient experimental data and lack of community interest. Of Note, non-classical HLA plays a crucial immunomodulatory role and regulates various immune responses. Recent studies revealed that non-classical HLA (HLA-E &amp; HLA-G) based immunotherapies have many advantages over classical HLA based-immunotherapy, particularly against COVID-19. In order to facilitate the scientific community, we have developed an artificial intelligence-based method for predicting binders of non-classical HLA alleles (HLA-G and HLA-E). All the models were trained and tested on experimentally validated data obtained from the recent release of IEDB. The machine learning based-models achieved more than 0.98 AUC for HLA-G alleles on validation or independent dataset. Similarly, our models achieved the highest AUC of 0.96 and 0.88 on the validation dataset for HLA-E*01:01, HLA-E*01:03, respectively. We have summarized the models developed in the past for non-classical HLA binders and compared with the models developed in this study. Moreover, we have also predicted the non-classical HLA binders in the spike protein of different variants of virus causing COVID-19 including omicron (B.1.1.529) to facilitate the community. One of the major challenges in the field of immunotherapy is to identify the promiscuous binders or antigenic regions that can bind to a large number of HLA alleles. In order to predict the promiscuous binders for the non-classical HLA alleles, we developed a web server HLAncPred (<ext-link ext-link-type="uri" xlink:href="https://webs.iiitd.edu.in/raghava/hlancpred">https://webs.iiitd.edu.in/raghava/hlancpred</ext-link>), and a standalone package.</p></abstract><kwd-group><kwd>Non-classical HLA</kwd><kwd>Binders</kwd><kwd>COVID-19</kwd><kwd>Prediction</kwd><kwd>Web server</kwd><kwd>Standalone</kwd></kwd-group></article-meta></front><body><sec id="S1" sec-type="intro"><title>Introduction</title><p id="P2">Human leukocyte antigens (HLA) are an essential part of our immune system and displayed on the cell surface for antigen presentation to activate immune responses [<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R2">2</xref>]. In humans, the highly polymorphic HLA Class-I and II complex is located at chromosome 6p21.31 [<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>]. More than 23000 Class-I and 8600 Class-II HLA alleles have been already reported across the globe in different ethnic groups according to IMGT/HLA database, 2020 version [<xref ref-type="bibr" rid="R5">5</xref>]. HLA Class-I genes further categorized into two major groups, i.e., classical (HLA-A, -B, -C) and non-classical (HLA-G, -E, -F) genes. The classical genes present antigenic peptide ligands on infected cells to CD8+ T cells and activate the immune response. On the other side, non-classical Class-I molecules moderate the immune response by inhibiting/activating stimuli of natural killer and CD8+ T cells [<xref ref-type="bibr" rid="R6">6</xref>]. HLA molecules protect us from several diseases by inducing and regulating immune responses [<xref ref-type="bibr" rid="R7">7</xref>-<xref ref-type="bibr" rid="R9">9</xref>]. At the same time, adverse effects have been shown in various ethnic groups due to the alteration in the expression of HLA alleles and HLA-peptide binding regions. This malfunctioning in the HLA-peptide binding grooves may lead to severe autoimmune disorders, cancer development, metastatic progression, and poor prognosis [<xref ref-type="bibr" rid="R10">10</xref>-<xref ref-type="bibr" rid="R13">13</xref>].</p><p id="P3">Recently, several studies report that the less explored non-classical alleles (HLA-G and HLA-E) play immunomodulatory roles [<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R14">14</xref>-<xref ref-type="bibr" rid="R16">16</xref>] in both innate and adaptive immune system (<xref ref-type="fig" rid="F1">Figure 1</xref>). Of note, HLA-G possess four membrane bound isoforms and three soluble isoforms; interact with ILT-2, ILT-4, KIR2DL4, NKG2A/CD94 receptors, etc [<xref ref-type="bibr" rid="R17">17</xref>-<xref ref-type="bibr" rid="R19">19</xref>]. Previously, researcher believe that HLA-G molecules are only identified at the maternal-fetal interface, but recent studies revealed that the altered expression of HLA-G may leads to the development of cancers, auto-immune, inflammatory diseases and COVID-19 [<xref ref-type="bibr" rid="R20">20</xref>-<xref ref-type="bibr" rid="R27">27</xref>]. In addition, HLA-G inhibit the activation of immune cells including CD8+ T, dendritic, and natural killer cells during parasite and viral infections (such as influenza A virus, herpes, coronavirus, etc) [<xref ref-type="bibr" rid="R28">28</xref>-<xref ref-type="bibr" rid="R30">30</xref>]. These viral infections leads to the over-expression of HLA-G molecule and build an immune tolerance microenvironment. On the opposite side, HLA-E is monomorphic in nature, possesses low polymorphism and bound to the highly conserved peptides/epitopes. HLA-E regulates immune cells (NK cells and CD8+ T cells) by interacting with inhibiting receptor’s (NKG2A/CD94, NKG2B/CD94) and activating receptor (NKG2C/CD94) [<xref ref-type="bibr" rid="R31">31</xref>].</p><p id="P4">There are two well-known mechanisms for antigen representation by HLA-E alleles, which decide the cells’ fate. HLA-E binds to the peptide fragments descended from the signal sequence of other class Ia HLA-alleles, and this representation leads to the inhibition of NK cell functions by interacting with the NKG2A/CD94 receptors on NK cells. However, some studies revealed that the peptides from the virus (such as SARS-CoV-2, Epstein Barr Virus, Cytomegalovirus, and Hepatitis C Virus) are presented by HLA-E on the cell surface and recognised by virus specific immune cells which further activate the immune responses [<xref ref-type="bibr" rid="R32">32</xref>-<xref ref-type="bibr" rid="R39">39</xref>]. Moreover, CD8+ T-cell interaction with HLA-E leads to the production of anti-inflammatory cytokines (TGF-b, IL-4, IL-10), which is responsible for the down-regulation of pro-inflammatory cytokines production and, therefore, inhibiting the cytokine storm which plays a crucial role in the COVID-19 pathogenesis. The inhibition of cytokine storm also lowers the degree of tissue damage [<xref ref-type="bibr" rid="R40">40</xref>]. Several studies reveals that HLA-E inhibits NK mediated lysis, cytotoxicity, cytokine secretion, and tumor proliferation [<xref ref-type="bibr" rid="R39">39</xref>, <xref ref-type="bibr" rid="R41">41</xref>-<xref ref-type="bibr" rid="R43">43</xref>], as represented in <xref ref-type="fig" rid="F1">Figure 1</xref>. These findings suggest that HLA-G and HLA-E could be essential immune checkpoint molecules for designing novel immunotherapies or subunit vaccines against a wide range of diseases.</p><p id="P5">Thus, there is a need to develop methods for predicting non-classical HLA binders. Though numerous computational methods have been developed in the past for predicting HLA binder but majorly focused on classical HLA [<xref ref-type="bibr" rid="R44">44</xref>-<xref ref-type="bibr" rid="R50">50</xref>]. Only a few tools incorporate models for predicting binders for non-classical HLA alleles. Best of our knowledge no tool has been explicitly developed for predicting non-classical HLA binders. This study is dedicated for non-classical HLA, where a systematic attempt has been made to develop models for predicting non-classical HLA binders. We obtained and examined all experimentally validated non-classical HLA binders from IEDB. Based on availability of sufficient data in IEDB, we developed models for predicting binders for following non-classical alleles HLA-G*01:01, HLA-G*01:03, HLA-G*01:04, HLA-E*01:01 and HLA-E*01:03. We have used various machine learning models for the better prediction of non-classical HLA binders.</p></sec><sec id="S2" sec-type="materials | methods"><title>Material and methods</title><sec id="S3"><title>Dataset collection and pre-processing</title><p id="P6">We have collected the experimentally validated non-classical Class-I HLA-binding peptides, i.e., 1135 HLA-E and 5151 HLA-G, from the immune epitope database (IEDB), accessed on 26 October 2021. Further, we removed redundant peptides with lengths (greater than 15 or less than 8) from the dataset. After that, we obtained 142 and 723 unique peptides for HLA-E*01:01 and -E*01:03 alleles, respectively. Similarly, we get 2633, 751, and 812 unique binding peptides for HLA-G*01:01, -G*01:03, and -G*01:04 alleles, respectively. One of the major challenge in this type of study is the availability of negative dataset. Due to limited number of negative peptides in IEDB, we randomly generate the HLA-G, HLA-E non-binding peptides (length 8-15 residues) from the Swiss-Prot [<xref ref-type="bibr" rid="R51">51</xref>] database (March 2021 release). Finally, we obtained positive and negative dataset corresponding to each allele as represented in <xref ref-type="table" rid="T1">Table 1</xref>.</p></sec><sec id="S4"><title>Amino acid composition</title><p id="P7">Amino acid composition (AAC) of the positive and negative dataset for each allele is computed to understand the compositional similarity in different peptide sequences. The following equation, is used to compute AAC for HLA-G and HLA-E alleles binder/non-binder peptides. <disp-formula id="FD1"><mml:math id="M1"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>C</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mi>A</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>R</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mi>T</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mtext> </mml:mtext><mml:mi>n</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mtext> </mml:mtext><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mtext> </mml:mtext><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mi>e</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> where AAC<sub>i</sub> and AAR<sub>i</sub> are the percentage composition and number of residues of type i in a peptide, respectively.</p></sec><sec id="S5"><title>Two Sample Logo (TSL)</title><p id="P8">In the current study, we performed amino-acid positional analysis using TSL tool [<xref ref-type="bibr" rid="R52">52</xref>], utilizing fixed-length peptide sequences used in previous studies [<xref ref-type="bibr" rid="R53">53</xref>-<xref ref-type="bibr" rid="R55">55</xref>]. In our dataset, the minimum length of peptides is eight, and hence, we create fixed-length peptides having sixteen residues. In order to create a fixed-length vector, we picked eight residues from N-terminal and eight residues from C-terminal; further, we merged the two sequences and got the final sixteen residue peptides for each positive and negative dataset.</p></sec><sec id="S6"><title>Feature generation</title><p id="P9">In this study, we used Pfeature [<xref ref-type="bibr" rid="R56">56</xref>] to calculate the binary profile for each peptide belong to binder and non-binder class. In order to calculate the binary profiles the length of the variable should be fixed, but the length of the peptides were varying from 8 to 15. Thus, to generate the fixed length vector, we extracted same number of residues from the N- and C-terminal of the peptides. Since, the minimum length of the peptides was 8, hence we chose to select the eight residues from each end and designed different patterns to calculate features. First, eight residues were selected from N-terminal, and designated as N<sub>8</sub> patterns; similarly, eight residues were chosen from C-terminal and referred as C<sub>8</sub> residues. Another patterns of length 16 were generated by joining the eight residues from N- and C-terminal and referred as N<sub>8</sub>C<sub>8</sub>. For the afore-mentioned patterns, each amino acid is represented by the vector of length 20, where each element represents the presence/absence of that residues, where presence was designated as “1” and absence was presented by “0”. For instance, residue “A” was represented as by vector 1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0; hence, total length of vector generated for patterns N<sub>8</sub> and C<sub>8</sub> was 160 (20*8) and for N<sub>8</sub>C<sub>8</sub> its 320 (20*16). Likewise, patterns of peptides with maximum length (i.e., 15 amino acids) were generated and termed as AA<sub>15</sub> and binary profile was calculated. In this case, residues “X” were added in the peptides having length less than 15. For example, 7 “X” were added in the peptide having length equal to 8, in order to make its length 15, such as peptide “VYIKHPVS” became “VYIKHPVSXXXXXXX”. In this scenario, each amino acid is represented by the vector size of 21, where last element exhibited presence/absence of “X”. Residue “V” is represented by vector 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0 and “X” is presented as 0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1.</p></sec><sec id="S7"><title>Machine learning techniques</title><p id="P10">Several machine learning methods have been employed to classify the positive and negative non-classical HLA-binding peptides. Here, we have used numerous machine learning classifiers such as Decision Tree (DT), Support Vector Classifier (SVC), Random Forest (RF), XGBoost (XGB), Logistic Regression (LR), ExtraTree classifier (ET), Gaussian Naive Bayes (GNB), and k-nearest neighbors (KNN) using scikit learn python-based package [<xref ref-type="bibr" rid="R57">57</xref>].</p></sec><sec id="S8"><title>Five-fold cross-validation</title><p id="P11">We have applied a 5-fold cross-validation technique to evade the curse of biasness and overfitting in the generated models. It is one of the most crucial steps to evaluate the prediction model. In this approach, the entire dataset is partitioned into five parts, out of which four are used in training, and the resulted model is tested on the left one. The exact process is reproduced five times so that each part gets the opportunity to act as the testing dataset. Ultimately, the final performance is represented as the average of the performance of the five models that resulted from the five iterations.</p></sec><sec id="S9"><title>Evaluation parameters</title><p id="P12">Several parameters can be employed to assess the prediction models, which can be broadly classified into two categories termed as threshold-dependent and -independent parameters. In this study, we have determined sensitivity, specificity, accuracy, F1-score, and Matthews correlation coefficient (MCC) as the threshold-dependent parameters, whereas Area Under Receiver Operating Characteristics (AUC) curve is calculated as the threshold-independent parameter. Sensitivity (<xref ref-type="disp-formula" rid="FD2">equation 1</xref>) is the measure of the ability of the model to correctly predict the binders, whereas specificity (<xref ref-type="disp-formula" rid="FD3">equation 2</xref>) accounts for the percentage of correctly predicted non-binders. Accuracy (<xref ref-type="disp-formula" rid="FD4">equation 3</xref>) exhibits the percentage of the correctly predicted binders and non-binders, F1-score (<xref ref-type="disp-formula" rid="FD5">equation 4</xref>) captures the balance between precision and recall, and MCC (<xref ref-type="disp-formula" rid="FD6">equation 5</xref>) explains the relation between the predicted and observed values. AUC is a plot between the sensitivity and 1-specificity, which captures the ability of the model to distinguish between the classes. <disp-formula id="FD2"><label>[1]</label><mml:math id="M2"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mi>S</mml:mi><mml:mi>e</mml:mi><mml:mi>n</mml:mi><mml:mi>s</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>i</mml:mi><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> <disp-formula id="FD3"><label>[2]</label><mml:math id="M3"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mi>S</mml:mi><mml:mi>p</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>t</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> <disp-formula id="FD4"><label>[3]</label><mml:math id="M4"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mi>A</mml:mi><mml:mi>c</mml:mi><mml:mi>c</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>a</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> <disp-formula id="FD5"><label>[4]</label><mml:math id="M5"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mi>F</mml:mi><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mrow><mml:mi>S</mml:mi><mml:mi>c</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> <disp-formula id="FD6"><label>[5]</label><mml:math id="M6"><mml:mtable><mml:mtr><mml:mtd><mml:mstyle displaystyle="true"><mml:mrow><mml:mi>M</mml:mi><mml:mi>C</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:msqrt><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>N</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:msqrt></mml:mfrac></mml:mstyle></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> Where, T<sub>P</sub>, T<sub>N</sub>, F<sub>P</sub> and F<sub>N</sub> stands for true positive, true negative, false positive and false negative, respectively.</p></sec></sec><sec id="S10" sec-type="results"><title>Results</title><sec id="S11"><title>Composition analysis</title><p id="P13">The average amino acid composition of HLA-G and HLA-E binding and non-binding peptides are represented in <xref ref-type="fig" rid="F2">Figure 2</xref>. As shown in the graphs, the compositional difference in positive and negative dataset is clearly visible. HLA-G*01:01, -G*01:03, -G*01:04 alleles binders (i.e., positive peptides) have higher composition of residues such as Isoleucine (I), Lysine (K), Leucine (L) and Proline (P) as compared to non-binding peptides as depicted in <xref ref-type="fig" rid="F2">Figure 2</xref> (A, B, C). However, the average composition of Alanine (A), Leucine (L), Methionine (M), Proline (P) and Valine (V) residues is higher in HLA-E*01:01, -E*01:03 binding peptides in contrast to the negative dataset as shown in <xref ref-type="fig" rid="F2">Figure 2 (D, E)</xref>.</p></sec><sec id="S12"><title>Positional analysis</title><p id="P14">In order to analyze and study the preference or relative abundance of specific amino acid residues at a particular position in the non-classical HLA binder/non-binder sequences; we generate TSL plots (<xref ref-type="fig" rid="F3">Figure 3</xref>). Of note, we generated the fixed length peptide having sixteen residues, where the first eight residues represent the N-terminal and last eight residues are C-terminal of each peptide sequence. From the TSL analysis we found that amino acid ‘L’ is predominately preferred at 2<sup>nd</sup>, 7<sup>th</sup>, 8<sup>th</sup>, 9<sup>th</sup>, 10<sup>th</sup>, 11<sup>th</sup>, and 16<sup>th</sup> position in HLA-G*01:01 binding peptides (<xref ref-type="fig" rid="F3">Figure 3A</xref>); at position 2<sup>nd</sup>, 8<sup>th</sup>, 9<sup>th</sup>, 11<sup>th</sup>, and 16<sup>th</sup> in HLA-G*01:03 binders (<xref ref-type="fig" rid="F3">Figure 3B</xref>); and at position 2<sup>nd</sup>, 7<sup>th</sup>, 8<sup>th</sup>, 9<sup>th</sup>, 11<sup>th</sup>, and 16<sup>th</sup> in HLA-G*01:04 binding peptides (<xref ref-type="fig" rid="F3">Figure 3B</xref>). Whereas, ‘I’ is most preferred at 2<sup>nd</sup>, 3<sup>rd</sup>, 7<sup>th</sup>, 11<sup>th</sup>, 15<sup>th</sup>, and 16<sup>th</sup> position in all HLA-G alleles binders as shown in <xref ref-type="fig" rid="F3">Figure 3 (A, B, C)</xref>. On the other side, ‘P’ residue is preferentially located at 3<sup>rd</sup>, 4<sup>th</sup>, 7<sup>th</sup>, 11<sup>th</sup>, 14<sup>th</sup>, and 15<sup>th</sup> positions in HLA-E*01:01 binders and 4<sup>th</sup>, 6<sup>th</sup>, 7<sup>th</sup>, 12<sup>th</sup>, and 14<sup>th</sup> positions are predominantly occurred in HLA-E*01:03 binders. While ‘L’ amino acid is preferred at position 2<sup>nd</sup>, 8<sup>th</sup>, 9<sup>th</sup>, 10<sup>th</sup> in HLA-E*01:01, however 2<sup>nd</sup>, 6<sup>th</sup>, 9<sup>th</sup>, 12<sup>th</sup>, and 16<sup>th</sup> positions are mainly inhabited in HLA-E*01:03 binders.</p></sec><sec id="S13"><title>Machine learning-based prediction</title><p id="P15">In this study, we have implemented several classifiers such as GNB, XGB, RF, DT, SVC, ET, and LR to develop prediction models. We calculate binary profile-based features of positive and negative datasets (i.e., HLA-G*01:01, -G*01:03, -G*01:04, -E*01:01, and - E*01:03 binding and non-binding peptides). Initially, we generate four feature-sets (i.e., N<sub>8</sub>, C<sub>8</sub>, N<sub>8</sub>C<sub>8</sub>, and AA<sub>15</sub> binary profiles) using Pfeature standalone package. Then, we developed several machine learning models on each feature-set for HLA-G and HLA-E alleles.</p></sec><sec id="S14"><title>Performance of HLA-G alleles models</title><p id="P16">We compute performance of each allele dataset using various machine learning classifiers with four feature-sets as depicted in Supplementary Table S1. Further, we observed that AA<sub>15</sub> binary profiles based-models outperform other feature-sets with balanced sensitivity and specificity. As shown in <xref ref-type="table" rid="T2">Table 2</xref>, HLA-G*01:01 dataset achieved maximum AUC of 0.99 and accuracy &gt;95% on both training and validation dataset using SVC classifier (<xref ref-type="table" rid="T2">Table 2</xref>). ET based models also shows similar results on training and validation dataset with AUC of 0.99 and accuracy &gt;95% (<xref ref-type="table" rid="T2">Table 2</xref>). XGB classifier shows comparable performance on HLA-G*01:03 dataset, with maximum AUC 0.99 and 0.98; accuracy 92.26% and 91.69% on training and validation dataset, respectively. Whereas, RF, ET, and SVC classifiers outperform the other models and perform equivalent on HLA-G*01:04 dataset. With the maximum AUC of 0.98 and accuracy 93.07% and 95.39% on training and validation dataset as shown in <xref ref-type="table" rid="T2">Table 2</xref>. On the other side, DT, LR, KNN, GBM based-models poorly performed on each dataset. The complete results for each feature-set is provided in Supplementary Table S1.</p></sec><sec id="S15"><title>Performance of HLA-E alleles models</title><p id="P17">In this, we have used positive and negative datasets of HLA-E*01:01 and -E*01:03 alleles and developed various prediction models. For this dataset AA<sub>15</sub> binary profile-based features prevail other classifiers as indicated in the previous section results. As demonstrate in <xref ref-type="table" rid="T3">Table 3</xref>, the performance of ET based models outperform the other classifiers with an accuracy of 87.67% and 89.47%; AUC of 0.96 on training and validation dataset, respectively. Besides, RF and XGB based models perform quite well with balanced sensitivity and specificity, accuracy (86.78% and 87.72%), AUC (0.95 and 0.96) on training and validation dataset, respectively (<xref ref-type="table" rid="T3">Table 3</xref>). However, on HLA-E*01:03 dataset RF performed quite well, with AUC of 0.93 and 0.88; accuracy of 84.78% and 82.76% on training and validation dataset as shown in <xref ref-type="table" rid="T3">Table 3</xref>. Similarly, models based on ET also perform equivalent with very less difference in sensitivity and specificity (<xref ref-type="table" rid="T3">Table 3</xref>). The comprehensive results of all other feature-sets are provided in Supplementary Table S2.</p></sec><sec id="S16"><title>Comparison with existing methods</title><p id="P18">It is very important to compare this new method with the existing methods in order to understand the advantage/disadvantages. To validate our method, we compare the performance of our models with the existing methods (MHCflurry 2.0 and NetMHCpan 4.1). We have trained our models on the previous used dataset, which is provided by MHCflurry 2.0 for HLA-G alleles only, because in case of HLA-E the number of peptides used in previous methods is very less. Further, we validate the performance of all the methods on the updated IEDB positive binders of (HLA-G*01:01, -G*01:03, and -G*01:04) alleles. As shown in the results, HLA<sub>nc</sub>Pred outperform other methods for the prediction of HLA-G binding peptides with balanced sensitivity, specificity, and maximum accuracy (<xref ref-type="table" rid="T4">Table 4</xref>). Whereas, MHCflurry 2.0 also performs quite well on the prediction of binder/non-binding peptides of HLA-G*01:01 dataset but perform poor on other datasets. Similarly, we observed NetMHCpan 4.1 perform poorly on the validation dataset.</p></sec><sec id="S17"><title>Web-Server and Standalone Implementation</title><p id="P19">In the current study, for assisting the scientific community in the prediction and scanning of non-classical HLA-binder and non-binder peptides, we have developed a web-based service “HLA<sub>nc</sub>Pred” (<ext-link ext-link-type="uri" xlink:href="https://webs.iiitd.edu.in/raghava/hlancpred/">https://webs.iiitd.edu.in/raghava/hlancpred/</ext-link>). In this web-server we have used our best models for the better prediction of HLA-binders. The detail description of HLA<sub>nc</sub>Pred modules are given below.</p><list list-type="simple" id="L1"><list-item><label>(a)</label><p id="P20"><bold>PREDICT:</bold> The prediction module allow the users to identify the most promiscuous HLA-G (-G*01:01, -G*01:02, -G*01:03) and HLA-E (-E*01:01, -E*01:03) alleles binders and non-binder peptides. User can submit multiple peptides in the standard FASTA format in the provided box or can upload the input files and can select either single or more than one alleles for binding prediction. Server provide the results in the tabular format, with the input sequence, score and prediction (binder/non-binder).</p></list-item><list-item><label>(b)</label><p id="P21"><bold>SCAN:</bold> This module gives the facility to recognize the regions of protein which may binds to the non-classical alleles such as HLA-G*01:01, -G*01:02, -G*01:03, -E*01:01, -E*01:03, using the binary profiles. It also facilitates the users to choose any length of sequence for the prediction of binders. The other way round, here users can also scan a protein sequence to find out the novel peptides with the binding ability to HLA-G and HLA-E alleles. It will generate the fragments of length selected by the users and predict their activity. User can submit the one or multiple protein sequences in FASTA format and choose the allele(s) for the prediction. In addition, user can also choose the result mode i.e., graphical or tabular as represented in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p></list-item><list-item><label>(c)</label><p id="P22"><bold>PACKAGE:</bold> To serve scientific community, we also provide a python- and Perl-based command line package (<ext-link ext-link-type="uri" xlink:href="https://webs.iiitd.edu.in/raghava/hlancpred/stand.html">https://webs.iiitd.edu.in/raghava/hlancpred/stand.html</ext-link>) for prediction of non-classical binders at large scale and in the absence of internet. In addition, we have also develop a docker-based standalone package of HLA<sub>nc</sub>Pred and integrated into the ‘GPSRdocker’ package <ext-link ext-link-type="uri" xlink:href="https://webs.iiitd.edu.in/gpsrdocker/">https://webs.iiitd.edu.in/gpsrdocker/</ext-link> [<xref ref-type="bibr" rid="R58">58</xref>].</p></list-item><list-item><label>(d)</label><p id="P23"><bold>DOWNLOAD:</bold> Using this module users can download the datasets used in this study.</p></list-item></list></sec><sec id="S18"><title>Case Study: Non-classical HLA-binders in COVID-19 variants</title><p id="P24">Several studies have shown that HLA-allele binding sites significantly influence the severity of COVID-19 disease [<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R27">27</xref>, <xref ref-type="bibr" rid="R40">40</xref>, <xref ref-type="bibr" rid="R59">59</xref>]. Recently, World Health Organisation (WHO) reports that the spike protein of coronavirus has shown more than 30 mutations in the new SARS-CoV-2 variant B.1.1.529 (Omicron). In order to investigate the effect of mutations on the HLA-binding regions, we have used the reference spike protein of SARS-CoV-2 from NCBI. Further, we identified the substituted mutations named as (A67V, Δ69-70, T95I, G142D, Δ143-145, Δ211, L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F) associated with the spike protein of B.1.1.529 variant (<ext-link ext-link-type="uri" xlink:href="https://www.gisaid.org/hcov19-variants/">https://www.gisaid.org/hcov19-variants/</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://ayassbioscience.com/voc/">https://ayassbioscience.com/voc/</ext-link>). In addition, we have also considered mutations in other variants such as in alpha variant (B.1.1.7) seven mutations named as N501Y, A570D, D614G, P681H, T716I, S982A and D1118H; similarly in beta variant (B.1.351) nine mutations such as D80A, D215G, K417N, E484K, N501Y, D614G, A701V, L18F and R246I; and in delta (B.1.617.2) strain nine mutations namely T19R, T95I, G142D, R158G, L452R, T478K, D614G, P681R and D950N were reported in spike protein according to Centers for Disease Control and Prevention (CDC portal) and Indian SARS-CoV-2 Genomics Consortium.</p><p id="P25">We created the mutated spike protein sequence by substituting the new mutations in the reference protein sequence. Then, we utilize the “SCAN” module (with peptide length = 9) of HLA<sub>nc</sub>Pred server, for the identification of HLA-binding regions in the reference and altered spike proteins. After that, we mapped the disparities in the reference and variant spike protein sequences. We found that in alpha strain, a single substitution T716I in peptide “NSIAIPINF”, results in the gain of binding ability for HLA-G*01:01; similarly E484K substitution in “KGFNCYFPL” peptide made it a binder for HLA-G*01:03, HLA-G*01:04, and HLA-E*01:01. However, due to mutation L452R in peptide “KVGGNYNYR” results in the loss of binding ability for HLA-G*01:03, and HLA-G*01:04 in delta strain. In case of recent strain omicron (B.1.1.529), mutations has resulted into the changes in the binding ability of various regions of spike proteins as shown in <xref ref-type="table" rid="T5">Table 5</xref>. The complete results for the binding prediction for alpha, beta, delta and omicron strains are provided in Supplementary Table S3, S4, S5, and S6, respectively. We hope that these findings can be used by scientific community for further investigation and designing of potential immunotherapies/vaccines against the new or future COVID-19 strains.</p></sec></sec><sec id="S19" sec-type="discussion | conclusions"><title>Discussion and Conclusion</title><p id="P26">The non-classical HLA such as, HLA-G acts as an immunomodulatory molecule and natural guard while providing protection during fetus development [<xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R61">61</xref>], whereas, HLA-E triggers immune responses via activating inflammatory cytokines during viral infections [<xref ref-type="bibr" rid="R9">9</xref>, <xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R62">62</xref>, <xref ref-type="bibr" rid="R63">63</xref>]. Of note, the over-expression of HLA-G may induce the immune suppressive microenvironment, which may help in evading tumor cells from our innate and adaptive immune system. Studies have also shown that the abundant and aberrant expression of HLA-G leads to immune-mediated disorders such as multiple sclerosis, systemic lupus erythematosus [<xref ref-type="bibr" rid="R60">60</xref>, <xref ref-type="bibr" rid="R64">64</xref>, <xref ref-type="bibr" rid="R65">65</xref>]. Due to the monomorphic nature of non-classical HLA, the HLA-E restricted T cell immunotherapy may be given to a heterogenic population and possess many benefits over classical HLA-based therapies. Moreover, the activation of anti-inflammatory immune response by HLA-E interaction with CD8+ T-cell leads to the inhibition of cytokine storm and hence reduces the collateral tissue damage, which could be beneficial in treating COVID-19 patients [<xref ref-type="bibr" rid="R40">40</xref>]. On the other hand, HLA-G based immunotherapies have been shown to achieve encouraging results in solid-cancer treatments. Researchers have designed an anti-HLA-G CAR-T cells immunotherapy for the treatment of acute lymphoblastic leukemia and B-cell malignancies [<xref ref-type="bibr" rid="R66">66</xref>].</p><p id="P27">Therefore, it is the utmost need to develop an accurate prediction method for the identification of non-classical HLA-binder peptides. In last few decades, a number of HLA-peptide binding prediction methods have been developed, hitherto very limited research has been deployed in the non-classical binder prediction. To strength the previous works and to facilities the researchers working in this area, we developed a highly accurate and efficient tool dedicated to the binder prediction of non-classical HLA alleles. The dataset takes an important role in machine learning model development; thus, we have constructed our major dataset from IEDB. For the training and validation dataset we have used experimentally validated positive peptides i.e., HLA-G and HLA-E alleles binders and negative data is randomly generated using Swiss-Prot. The composition and TSL analysis indicates that non-classical HLA-binding peptides are enriched in Proline and Leucine amino acids. Furthermore, various models were developed using N<sub>8</sub>, C<sub>8</sub>, N<sub>8</sub>C<sub>8</sub>, and AA<sub>15</sub> binary profiles for each allele datasets. Our results indicate that, models developed on AA<sub>15</sub> binary profile-based features achieve highest performance (i.e., AUC 0.99 and accuracy &gt;95%) on training and validation dataset for HLA-G*01:01 allele using SVC classifier. We have used the best models for each non-classical HLA-binders and developed a web-server named “HLA<sub>nc</sub>Pred” to predict and scan non-classical HLA-binding peptides. We also provide the standalone package for the bulk scale non-classical HLA binder prediction.</p><p id="P28">Additionally, we utilized the SCAN module of our server for the prediction of HLA-binding/non-binding peptides in the spike protein of new strain of SARS-CoV-2 i.e., B.1.1.529 (Omicron). We identified 431 promiscuous binders, where 80, 155, 56, 57, and 83 binders were predicted for HLA-E*01:01,- E*01:03, -G*01:01, -G*01:03, -G*01:04 allele, respectively. From the prediction, we observed that due to the new mutations occurred in B.1.1.529 (Omicron) variant, several peptide regions have shown the opposite binding trait in comparison with the reference spike protein (<xref ref-type="table" rid="T5">Table 5</xref>). For instance, mutations Δ 211 and L212I, changed the binding behaviour of “DLPQGFSAL” peptide for all non-classical HLA alleles. These observations can benefit the scientific community for designing vaccine against the deadly virus. In addition, researches can use this tool to predict the binding peptides of non-classical HLA-alleles against different pathogenic, autoimmune and viral infections. We anticipate that this method will benefit the community working in the area of vaccine and HLA-based immunotherapy designing. The complete architecture of the HLA<sub>nc</sub>Pred is shown in Figure 5.</p></sec></body><back><ack id="S20"><title>Acknowledgements</title><p>Authors are thankful to the Department of Bio-Technology (DBT) and Department of Science and Technology (DST-INSPIRE) for fellowships and the financial support and Department of Computational Biology, IIITD New Delhi for infrastructure and facilities.</p><sec id="S21"><title>Funding Source</title><p>The current work has not received any specific grant from any funding agencies.</p></sec></ack><sec sec-type="data-availability" id="S22"><title>Data Availability Statement</title><p id="P29">All the datasets generated in this study are available at “HLA<sub>nc</sub>Pred” web server, <ext-link ext-link-type="uri" xlink:href="https://webs.iiitd.edu.in/raghava/hlancpred/down.php">https://webs.iiitd.edu.in/raghava/hlancpred/down.php</ext-link>.</p></sec><bio id="B1"><p id="P30"><bold>Author’s Biography</bold> <list list-type="order" id="L2"><list-item><p id="P31">Anjali Dhall is currently working as Ph.D. in Bioinformatics from Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.</p></list-item><list-item><p id="P32">Sumeet Patiyal is currently working as Ph.D. in Bioinformatics from Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.</p></list-item><list-item><p id="P33">Gajendra P. S. Raghava is currently working as Professor and Head of Department of Computational Biology, Indraprastha Institute of Information Technology, New Delhi, India.</p></list-item></list></p></bio><fn-group><fn id="FN1" fn-type="conflict"><p id="P34"><bold>Conflict of interest</bold></p><p id="P35">The authors declare no competing financial and non-financial interests.</p></fn><fn id="FN2" fn-type="con"><p id="P36"><bold>Authors’ contributions</bold></p><p id="P37">AD, SP and GPSR collected and processed the datasets. AD, SP and GPSR implemented the algorithms and developed the prediction models. AD, SP and GPSR analysed the results. SP, and AD created the back-end of the web server the front-end user interface. AD, SP, and GPSR penned the manuscript. GPSR conceived and coordinated the project. All authors have read and approved the final manuscript.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marshall</surname><given-names>JS</given-names></name><name><surname>Warrington</surname><given-names>R</given-names></name><name><surname>Watson</surname><given-names>W</given-names></name><etal/></person-group><article-title>An introduction to immunology and immunopathology</article-title><source>Allergy Asthma Clin Immunol</source><year>2018</year><volume>14</volume><fpage>49</fpage><pub-id pub-id-type="pmcid">PMC6156898</pub-id><pub-id pub-id-type="pmid">30263032</pub-id><pub-id pub-id-type="doi">10.1186/s13223-018-0278-1</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chaplin</surname><given-names>DD</given-names></name></person-group><article-title>Overview of the immune response</article-title><source>J Allergy Clin Immunol</source><year>2010</year><volume>125</volume><fpage>S3</fpage><lpage>23</lpage><pub-id pub-id-type="pmcid">PMC2923430</pub-id><pub-id pub-id-type="pmid">20176265</pub-id><pub-id pub-id-type="doi">10.1016/j.jaci.2009.12.980</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choo</surname><given-names>SY</given-names></name></person-group><article-title>The HLA system: genetics, immunology, clinical testing, and clinical implications</article-title><source>Yonsei Med J</source><year>2007</year><volume>48</volume><fpage>11</fpage><lpage>23</lpage><pub-id pub-id-type="pmcid">PMC2628004</pub-id><pub-id pub-id-type="pmid">17326240</pub-id><pub-id pub-id-type="doi">10.3349/ymj.2007.48.1.11</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beck</surname><given-names>S</given-names></name><name><surname>Trowsdale</surname><given-names>J</given-names></name></person-group><article-title>The human major histocompatability complex: lessons from the DNA sequence</article-title><source>Annu Rev Genomics Hum Genet</source><year>2000</year><volume>1</volume><fpage>117</fpage><lpage>137</lpage><pub-id pub-id-type="pmid">11701627</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Barker</surname><given-names>DJ</given-names></name><name><surname>Georgiou</surname><given-names>X</given-names></name><etal/></person-group><article-title>IPD-IMGT/HLA Database</article-title><source>Nucleic Acids Res</source><year>2020</year><volume>48</volume><fpage>D948</fpage><lpage>D955</lpage><pub-id pub-id-type="pmcid">PMC7145640</pub-id><pub-id pub-id-type="pmid">31667505</pub-id><pub-id pub-id-type="doi">10.1093/nar/gkz950</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uzhachenko</surname><given-names>RV</given-names></name><name><surname>Shanker</surname><given-names>A</given-names></name></person-group><article-title>CD8(+) T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity</article-title><source>Front Immunol</source><year>2019</year><volume>10</volume><elocation-id>1906</elocation-id><pub-id pub-id-type="pmcid">PMC6700470</pub-id><pub-id pub-id-type="pmid">31456803</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.01906</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Blackwell</surname><given-names>JM</given-names></name><name><surname>Jamieson</surname><given-names>SE</given-names></name><name><surname>Burgner</surname><given-names>D</given-names></name></person-group><article-title>HLA and infectious diseases</article-title><source>Clin Microbiol Rev</source><year>2009</year><volume>22</volume><fpage>370</fpage><lpage>385</lpage><comment>Table of Contents</comment><pub-id pub-id-type="pmcid">PMC2668228</pub-id><pub-id pub-id-type="pmid">19366919</pub-id><pub-id pub-id-type="doi">10.1128/CMR.00048-08</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tavasolian</surname><given-names>F</given-names></name><name><surname>Rashidi</surname><given-names>M</given-names></name><name><surname>Hatam</surname><given-names>GR</given-names></name><etal/></person-group><article-title>HLA, Immune Response, and Susceptibility to COVID-19</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>601886</elocation-id><pub-id pub-id-type="pmcid">PMC7820778</pub-id><pub-id pub-id-type="pmid">33488597</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.601886</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crux</surname><given-names>NB</given-names></name><name><surname>Elahi</surname><given-names>S</given-names></name></person-group><article-title>Human Leukocyte Antigen (HLA) and Immune Regulation: How Do Classical and Non-Classical HLA Alleles Modulate Immune Response to Human Immunodeficiency Virus and Hepatitis C Virus Infections?</article-title><source>Front Immunol</source><year>2017</year><volume>8</volume><fpage>832</fpage><pub-id pub-id-type="pmcid">PMC5513977</pub-id><pub-id pub-id-type="pmid">28769934</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.00832</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabapathy</surname><given-names>K</given-names></name><name><surname>Nam</surname><given-names>SY</given-names></name></person-group><article-title>Defective MHC class I antigen surface expression promotes cellular survival through elevated ER stress and modulation of p53 function</article-title><source>Cell Death Differ</source><year>2008</year><volume>15</volume><fpage>1364</fpage><lpage>1374</lpage><pub-id pub-id-type="pmid">18511935</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aptsiauri</surname><given-names>N</given-names></name><name><surname>Cabrera</surname><given-names>T</given-names></name><name><surname>Mendez</surname><given-names>R</given-names></name><etal/></person-group><article-title>Role of altered expression of HLA class I molecules in cancer progression</article-title><source>Adv Exp Med Biol</source><year>2007</year><volume>601</volume><fpage>123</fpage><lpage>131</lpage><pub-id pub-id-type="pmid">17712999</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mendez</surname><given-names>R</given-names></name><name><surname>Aptsiauri</surname><given-names>N</given-names></name><name><surname>Del Campo</surname><given-names>A</given-names></name><etal/></person-group><article-title>HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank</article-title><source>Cancer Immunol Immunother</source><year>2009</year><volume>58</volume><fpage>1507</fpage><lpage>1515</lpage><pub-id pub-id-type="pmid">19340423</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>LL</given-names></name><name><surname>Lock-Andersen</surname><given-names>J</given-names></name><name><surname>Hviid</surname><given-names>TV</given-names></name></person-group><article-title>The Pathophysiological Impact of HLA Class Ia and HLA-G Expression and Regulatory T Cells in Malignant Melanoma: A Review</article-title><source>J Immunol Res</source><year>2016</year><volume>2016</volume><elocation-id>6829283</elocation-id><pub-id pub-id-type="pmcid">PMC5141560</pub-id><pub-id pub-id-type="pmid">27999823</pub-id><pub-id pub-id-type="doi">10.1155/2016/6829283</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiot</surname><given-names>L</given-names></name><name><surname>Vu</surname><given-names>N</given-names></name><name><surname>Samson</surname><given-names>M</given-names></name></person-group><article-title>Immunomodulatory properties of HLA-G in infectious diseases</article-title><source>J Immunol Res</source><year>2014</year><volume>2014</volume><elocation-id>298569</elocation-id><pub-id pub-id-type="pmcid">PMC4009271</pub-id><pub-id pub-id-type="pmid">24839609</pub-id><pub-id pub-id-type="doi">10.1155/2014/298569</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murdaca</surname><given-names>G</given-names></name><name><surname>Contini</surname><given-names>P</given-names></name><name><surname>Negrini</surname><given-names>S</given-names></name><etal/></person-group><article-title>Immunoregulatory Role of HLA-G in Allergic Diseases</article-title><source>J Immunol Res</source><year>2016</year><volume>2016</volume><elocation-id>6865758</elocation-id><pub-id pub-id-type="pmcid">PMC4931064</pub-id><pub-id pub-id-type="pmid">27413762</pub-id><pub-id pub-id-type="doi">10.1155/2016/6865758</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rouas-Freiss</surname><given-names>N</given-names></name><name><surname>Khalil-Daher</surname><given-names>I</given-names></name><name><surname>Riteau</surname><given-names>B</given-names></name><etal/></person-group><article-title>The immunotolerance role of HLA-G</article-title><source>Semin Cancer Biol</source><year>1999</year><volume>9</volume><fpage>3</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">10092545</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>R</given-names></name><name><surname>Trentini</surname><given-names>A</given-names></name><name><surname>Bortolotti</surname><given-names>D</given-names></name><etal/></person-group><article-title>Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding</article-title><source>Mol Cell Biochem</source><year>2013</year><volume>381</volume><fpage>243</fpage><lpage>255</lpage><pub-id pub-id-type="pmid">23737137</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tronik-Le Roux</surname><given-names>D</given-names></name><name><surname>Renard</surname><given-names>J</given-names></name><name><surname>Verine</surname><given-names>J</given-names></name><etal/></person-group><article-title>Novel landscape of HLA-G isoforms expressed in clear cell renal cell carcinoma patients</article-title><source>Mol Oncol</source><year>2017</year><volume>11</volume><fpage>1561</fpage><lpage>1578</lpage><pub-id pub-id-type="pmcid">PMC5664004</pub-id><pub-id pub-id-type="pmid">28815885</pub-id><pub-id pub-id-type="doi">10.1002/1878-0261.12119</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>GT</given-names></name><name><surname>Celik</surname><given-names>AA</given-names></name><name><surname>Huyton</surname><given-names>T</given-names></name><etal/></person-group><article-title>NKG2A/CD94 Is a New Immune Receptor for HLA-G and Distinguishes Amino Acid Differences in the HLA-G Heavy Chain</article-title><source>Int J Mol Sci</source><year>2020</year><volume>21</volume><pub-id pub-id-type="pmcid">PMC7352787</pub-id><pub-id pub-id-type="pmid">32575403</pub-id><pub-id pub-id-type="doi">10.3390/ijms21124362</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carosella</surname><given-names>ED</given-names></name><name><surname>Gregori</surname><given-names>S</given-names></name><name><surname>Rouas-Freiss</surname><given-names>N</given-names></name><etal/></person-group><article-title>The role of HLA-G in immunity and hematopoiesis</article-title><source>Cell Mol Life Sci</source><year>2011</year><volume>68</volume><fpage>353</fpage><lpage>368</lpage><pub-id pub-id-type="pmid">21116680</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovats</surname><given-names>S</given-names></name><name><surname>Main</surname><given-names>EK</given-names></name><name><surname>Librach</surname><given-names>C</given-names></name><etal/></person-group><article-title>A class I antigen, HLA-G, expressed in human trophoblasts</article-title><source>Science</source><year>1990</year><volume>248</volume><fpage>220</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">2326636</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>CM</given-names></name><name><surname>Orr</surname><given-names>HT</given-names></name></person-group><article-title>Maternal/fetal interactions: the role of the MHC class I molecule HLA-G</article-title><source>Crit Rev Immunol</source><year>1993</year><volume>13</volume><fpage>207</fpage><lpage>224</lpage><pub-id pub-id-type="pmid">8110376</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shih Ie</surname><given-names>M</given-names></name></person-group><article-title>Application of human leukocyte antigen-G expression in the diagnosis of human cancer</article-title><source>Hum Immunol</source><year>2007</year><volume>68</volume><fpage>272</fpage><lpage>276</lpage><pub-id pub-id-type="pmcid">PMC1905833</pub-id><pub-id pub-id-type="pmid">17400063</pub-id><pub-id pub-id-type="doi">10.1016/j.humimm.2007.01.010</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheu</surname><given-names>J</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name></person-group><article-title>HLA-G and immune evasion in cancer cells</article-title><source>J Formos Med Assoc</source><year>2010</year><volume>109</volume><fpage>248</fpage><lpage>257</lpage><pub-id pub-id-type="pmid">20434034</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amiot</surname><given-names>L</given-names></name><name><surname>Ferrone</surname><given-names>S</given-names></name><name><surname>Grosse-Wilde</surname><given-names>H</given-names></name><etal/></person-group><article-title>Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention?</article-title><source>Cell Mol Life Sci</source><year>2011</year><volume>68</volume><fpage>417</fpage><lpage>431</lpage><pub-id pub-id-type="pmcid">PMC3426238</pub-id><pub-id pub-id-type="pmid">21063893</pub-id><pub-id pub-id-type="doi">10.1007/s00018-010-0583-4</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rizzo</surname><given-names>R</given-names></name><name><surname>Bortolotti</surname><given-names>D</given-names></name><name><surname>Bolzani</surname><given-names>S</given-names></name><etal/></person-group><article-title>HLA-G Molecules in Autoimmune Diseases and Infections</article-title><source>Front Immunol</source><year>2014</year><volume>5</volume><fpage>592</fpage><pub-id pub-id-type="pmcid">PMC4235267</pub-id><pub-id pub-id-type="pmid">25477881</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2014.00592</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zidi</surname><given-names>I</given-names></name></person-group><article-title>Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E</article-title><source>Hum Immunol</source><year>2020</year><volume>81</volume><fpage>697</fpage><lpage>701</lpage><pub-id pub-id-type="pmcid">PMC7539797</pub-id><pub-id pub-id-type="pmid">33046268</pub-id><pub-id pub-id-type="doi">10.1016/j.humimm.2020.10.001</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sabbagh</surname><given-names>A</given-names></name><name><surname>Sonon</surname><given-names>P</given-names></name><name><surname>Sadissou</surname><given-names>I</given-names></name><etal/></person-group><article-title>The role of HLA-G in parasitic diseases</article-title><source>HLA</source><year>2018</year><volume>91</volume><fpage>255</fpage><lpage>270</lpage><pub-id pub-id-type="pmid">29368453</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Catamo</surname><given-names>E</given-names></name><name><surname>Zupin</surname><given-names>L</given-names></name><name><surname>Crovella</surname><given-names>S</given-names></name><etal/></person-group><article-title>Non-classical MHC-I human leukocyte antigen (HLA-G) in hepatotropic viral infections and in hepatocellular carcinoma</article-title><source>Hum Immunol</source><year>2014</year><volume>75</volume><fpage>1225</fpage><lpage>1231</lpage><pub-id pub-id-type="pmid">25318079</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dias</surname><given-names>FC</given-names></name><name><surname>Castelli</surname><given-names>EC</given-names></name><name><surname>Collares</surname><given-names>CV</given-names></name><etal/></person-group><article-title>The Role of HLA-G Molecule and HLA-G Gene Polymorphisms in Tumors, Viral Hepatitis, and Parasitic Diseases</article-title><source>Front Immunol</source><year>2015</year><volume>6</volume><fpage>9</fpage><pub-id pub-id-type="pmcid">PMC4313582</pub-id><pub-id pub-id-type="pmid">25699038</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2015.00009</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kraemer</surname><given-names>T</given-names></name><name><surname>Blasczyk</surname><given-names>R</given-names></name><name><surname>Bade-Doeding</surname><given-names>C</given-names></name></person-group><article-title>HLA-E: a novel player for histocompatibility</article-title><source>J Immunol Res</source><year>2014</year><volume>2014</volume><elocation-id>352160</elocation-id><pub-id pub-id-type="pmcid">PMC4221882</pub-id><pub-id pub-id-type="pmid">25401109</pub-id><pub-id pub-id-type="doi">10.1155/2014/352160</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joosten</surname><given-names>SA</given-names></name><name><surname>Sullivan</surname><given-names>LC</given-names></name><name><surname>Ottenhoff</surname><given-names>TH</given-names></name></person-group><article-title>Characteristics of HLA-E Restricted T-Cell Responses and Their Role in Infectious Diseases</article-title><source>J Immunol Res</source><year>2016</year><volume>2016</volume><elocation-id>2695396</elocation-id><pub-id pub-id-type="pmcid">PMC5028793</pub-id><pub-id pub-id-type="pmid">27699181</pub-id><pub-id pub-id-type="doi">10.1155/2016/2695396</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Pietra</surname><given-names>G</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Identification of HLA-E-specific alloreactive T lymphocytes: a cell subset that undergoes preferential expansion in mixed lymphocyte culture and displays a broad cytolytic activity against allogeneic cells</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><fpage>11328</fpage><lpage>11333</lpage><pub-id pub-id-type="pmcid">PMC123256</pub-id><pub-id pub-id-type="pmid">12167676</pub-id><pub-id pub-id-type="doi">10.1073/pnas.172369799</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garcia</surname><given-names>P</given-names></name><name><surname>Llano</surname><given-names>M</given-names></name><name><surname>de Heredia</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Human T cell receptor-mediated recognition of HLA-E</article-title><source>Eur J Immunol</source><year>2002</year><volume>32</volume><fpage>936</fpage><lpage>944</lpage><pub-id pub-id-type="pmid">11920559</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>PB</given-names></name><name><surname>Livbjerg</surname><given-names>AH</given-names></name><name><surname>Hansen</surname><given-names>HJ</given-names></name><etal/></person-group><article-title>Epstein-Barr virus peptide presented by HLA-E is predominantly recognized by CD8(bright) cells in multiple sclerosis patients</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><elocation-id>e46120</elocation-id><pub-id pub-id-type="pmcid">PMC3457977</pub-id><pub-id pub-id-type="pmid">23049954</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0046120</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pietra</surname><given-names>G</given-names></name><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Mazzarino</surname><given-names>P</given-names></name><etal/></person-group><article-title>HLA-E-restricted recognition of cytomegalovirus-derived peptides by human CD8+ cytolytic T lymphocytes</article-title><source>Proc Natl Acad Sci U S A</source><year>2003</year><volume>100</volume><fpage>10896</fpage><lpage>10901</lpage><pub-id pub-id-type="pmcid">PMC196899</pub-id><pub-id pub-id-type="pmid">12960383</pub-id><pub-id pub-id-type="doi">10.1073/pnas.1834449100</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mazzarino</surname><given-names>P</given-names></name><name><surname>Pietra</surname><given-names>G</given-names></name><name><surname>Vacca</surname><given-names>P</given-names></name><etal/></person-group><article-title>Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion</article-title><source>Eur J Immunol</source><year>2005</year><volume>35</volume><fpage>3240</fpage><lpage>3247</lpage><pub-id pub-id-type="pmid">16224817</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romagnani</surname><given-names>C</given-names></name><name><surname>Pietra</surname><given-names>G</given-names></name><name><surname>Falco</surname><given-names>M</given-names></name><etal/></person-group><article-title>HLA-E-restricted recognition of human cytomegalovirus by a subset of cytolytic T lymphocytes</article-title><source>Hum Immunol</source><year>2004</year><volume>65</volume><fpage>437</fpage><lpage>445</lpage><pub-id pub-id-type="pmid">15172443</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crew</surname><given-names>MD</given-names></name><name><surname>Cannon</surname><given-names>MJ</given-names></name><name><surname>Phanavanh</surname><given-names>B</given-names></name><etal/></person-group><article-title>An HLA-E single chain trimer inhibits human NK cell reactivity towards porcine cells</article-title><source>Mol Immunol</source><year>2005</year><volume>42</volume><fpage>1205</fpage><lpage>1214</lpage><pub-id pub-id-type="pmid">15829309</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caccamo</surname><given-names>N</given-names></name><name><surname>Sullivan</surname><given-names>LC</given-names></name><name><surname>Brooks</surname><given-names>AG</given-names></name><etal/></person-group><article-title>Harnessing HLA-E-restricted CD8 T lymphocytes for adoptive cell therapy of patients with severe COVID-19</article-title><source>Br J Haematol</source><year>2020</year><volume>190</volume><fpage>e185</fpage><lpage>e187</lpage><pub-id pub-id-type="pmcid">PMC7301003</pub-id><pub-id pub-id-type="pmid">32480418</pub-id><pub-id pub-id-type="doi">10.1111/bjh.16895</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>N</given-names></name><name><surname>Llano</surname><given-names>M</given-names></name><name><surname>Carretero</surname><given-names>M</given-names></name><etal/></person-group><article-title>HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>5199</fpage><lpage>5204</lpage><pub-id pub-id-type="pmcid">PMC20238</pub-id><pub-id pub-id-type="pmid">9560253</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.9.5199</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>HLA-E Binding Peptide as a Potential Therapeutic Candidate for High-Risk Multiple Myeloma</article-title><source>Front Oncol</source><year>2021</year><volume>11</volume><elocation-id>670673</elocation-id><pub-id pub-id-type="pmcid">PMC8219970</pub-id><pub-id pub-id-type="pmid">34178656</pub-id><pub-id pub-id-type="doi">10.3389/fonc.2021.670673</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhen</surname><given-names>Z</given-names></name><name><surname>Yang</surname><given-names>K</given-names></name><name><surname>Ye</surname><given-names>L</given-names></name><etal/></person-group><article-title>HLA-E inhibitor enhances the killing of neuroblastoma stem cells by co-cultured dendritic cells and cytokine-induced killer cells loaded with membrane-based microparticles</article-title><source>Am J Cancer Res</source><year>2017</year><volume>7</volume><fpage>334</fpage><lpage>345</lpage><pub-id pub-id-type="pmcid">PMC5336506</pub-id><pub-id pub-id-type="pmid">28337381</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Raghava</surname><given-names>GP</given-names></name></person-group><article-title>ProPred: prediction of HLA-DR binding sites</article-title><source>Bioinformatics</source><year>2001</year><volume>17</volume><fpage>1236</fpage><lpage>1237</lpage><pub-id pub-id-type="pmid">11751237</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Raghava</surname><given-names>GP</given-names></name></person-group><article-title>ProPred1: prediction of promiscuous MHC Class-I binding sites</article-title><source>Bioinformatics</source><year>2003</year><volume>19</volume><fpage>1009</fpage><lpage>1014</lpage><pub-id pub-id-type="pmid">12761064</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>B</given-names></name><name><surname>Khodadoust</surname><given-names>MS</given-names></name><name><surname>Olsson</surname><given-names>N</given-names></name><etal/></person-group><article-title>Predicting HLA class II antigen presentation through integrated deep learning</article-title><source>Nat Biotechnol</source><year>2019</year><volume>37</volume><fpage>1332</fpage><lpage>1343</lpage><pub-id pub-id-type="pmcid">PMC7075463</pub-id><pub-id pub-id-type="pmid">31611695</pub-id><pub-id pub-id-type="doi">10.1038/s41587-019-0280-2</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jurtz</surname><given-names>V</given-names></name><name><surname>Paul</surname><given-names>S</given-names></name><name><surname>Andreatta</surname><given-names>M</given-names></name><etal/></person-group><article-title>NetMHCpan-4.0: Improved Peptide-MHC Class I Interaction Predictions Integrating Eluted Ligand and Peptide Binding Affinity Data</article-title><source>J Immunol</source><year>2017</year><volume>199</volume><fpage>3360</fpage><lpage>3368</lpage><pub-id pub-id-type="pmcid">PMC5679736</pub-id><pub-id pub-id-type="pmid">28978689</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.1700893</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Donnell</surname><given-names>TJ</given-names></name><name><surname>Rubinsteyn</surname><given-names>A</given-names></name><name><surname>Laserson</surname><given-names>U</given-names></name></person-group><article-title>MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing</article-title><source>Cell Syst</source><year>2020</year><volume>11</volume><fpage>42</fpage><lpage>48</lpage><elocation-id>e47</elocation-id><pub-id pub-id-type="pmid">32711842</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>MATHLA: a robust framework for HLA-peptide binding prediction integrating bidirectional LSTM and multiple head attention mechanism</article-title><source>BMC Bioinformatics</source><year>2021</year><volume>22</volume><fpage>7</fpage><pub-id pub-id-type="pmcid">PMC7787246</pub-id><pub-id pub-id-type="pmid">33407098</pub-id><pub-id pub-id-type="doi">10.1186/s12859-020-03946-z</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhasin</surname><given-names>M</given-names></name><name><surname>Raghava</surname><given-names>GP</given-names></name></person-group><article-title>A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes</article-title><source>J Biosci</source><year>2007</year><volume>32</volume><fpage>31</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17426378</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bairoch</surname><given-names>A</given-names></name><name><surname>Apweiler</surname><given-names>R</given-names></name></person-group><article-title>The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000</article-title><source>Nucleic Acids Res</source><year>2000</year><volume>28</volume><fpage>45</fpage><lpage>48</lpage><pub-id pub-id-type="pmcid">PMC102476</pub-id><pub-id pub-id-type="pmid">10592178</pub-id><pub-id pub-id-type="doi">10.1093/nar/28.1.45</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vacic</surname><given-names>V</given-names></name><name><surname>Iakoucheva</surname><given-names>LM</given-names></name><name><surname>Radivojac</surname><given-names>P</given-names></name></person-group><article-title>Two Sample Logo: a graphical representation of the differences between two sets of sequence alignments</article-title><source>Bioinformatics</source><year>2006</year><volume>22</volume><fpage>1536</fpage><lpage>1537</lpage><pub-id pub-id-type="pmid">16632492</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dhall</surname><given-names>A</given-names></name><name><surname>Patiyal</surname><given-names>S</given-names></name><name><surname>Sharma</surname><given-names>N</given-names></name><etal/></person-group><article-title>Computer-aided prediction and design of IL-6 inducing peptides: IL-6 plays a crucial role in COVID-19</article-title><source>Brief Bioinform</source><year>2021</year><volume>22</volume><fpage>936</fpage><lpage>945</lpage><pub-id pub-id-type="pmcid">PMC7665369</pub-id><pub-id pub-id-type="pmid">33034338</pub-id><pub-id pub-id-type="doi">10.1093/bib/bbaa259</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>V</given-names></name><name><surname>Patiyal</surname><given-names>S</given-names></name><name><surname>Dhall</surname><given-names>A</given-names></name><etal/></person-group><article-title>B3Pred: A Random-Forest-Based Method for Predicting and Designing Blood-Brain Barrier Penetrating Peptides</article-title><source>Pharmaceutics</source><year>2021</year><volume>13</volume><pub-id pub-id-type="pmcid">PMC8399279</pub-id><pub-id pub-id-type="pmid">34452198</pub-id><pub-id pub-id-type="doi">10.3390/pharmaceutics13081237</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patiyal</surname><given-names>S</given-names></name><name><surname>Agrawal</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>V</given-names></name><etal/></person-group><article-title>NAGbinder: An approach for identifying N-acetylglucosamine interacting residues of a protein from its primary sequence</article-title><source>Protein Sci</source><year>2020</year><volume>29</volume><fpage>201</fpage><lpage>210</lpage><pub-id pub-id-type="pmcid">PMC6933864</pub-id><pub-id pub-id-type="pmid">31654438</pub-id><pub-id pub-id-type="doi">10.1002/pro.3761</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pande</surname><given-names>A</given-names></name><name><surname>Patiyal</surname><given-names>S</given-names></name><name><surname>Lathwal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Computing wide range of protein/peptide features from their sequence and structure</article-title><source>BioRxiv</source><year>2019</year><elocation-id>599126</elocation-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pedregosa</surname><given-names>F</given-names></name><name><surname>Varoquaux</surname><given-names>G</given-names></name><name><surname>Gramfort</surname><given-names>A</given-names></name><etal/></person-group><article-title>Scikit-learn: Machine Learning in Python</article-title><source>Journal of Machine Learning Research</source><year>2012</year><volume>12</volume><fpage>2825</fpage><lpage>2830</lpage></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>P</given-names></name><name><surname>Kumar</surname><given-names>R</given-names></name><name><surname>Usmani</surname><given-names>SS</given-names></name><etal/></person-group><article-title>GPSRdocker: a Docker-based resource for genomics, proteomics and systems biology</article-title><source>BioRxiv</source><year>2019</year><elocation-id>827766</elocation-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouayad</surname><given-names>A</given-names></name></person-group><article-title>Features of HLA class I expression and its clinical relevance in SARS-CoV-2: What do we know so far?</article-title><source>Rev Med Virol</source><year>2021</year><volume>31</volume><elocation-id>e2236</elocation-id><pub-id pub-id-type="pmcid">PMC8250062</pub-id><pub-id pub-id-type="pmid">33793006</pub-id><pub-id pub-id-type="doi">10.1002/rmv.2236</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amodio</surname><given-names>G</given-names></name><name><surname>Gregori</surname><given-names>S</given-names></name></person-group><article-title>HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>1178</elocation-id><pub-id pub-id-type="pmcid">PMC7360675</pub-id><pub-id pub-id-type="pmid">32733439</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01178</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>H</given-names></name></person-group><article-title>Roles of HLA-G in the Maternal-Fetal Immune Microenvironment</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>592010</elocation-id><pub-id pub-id-type="pmcid">PMC7642459</pub-id><pub-id pub-id-type="pmid">33193435</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.592010</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanevskiy</surname><given-names>L</given-names></name><name><surname>Erokhina</surname><given-names>S</given-names></name><name><surname>Kobyzeva</surname><given-names>P</given-names></name><etal/></person-group><article-title>Dimorphism of HLA-E and its Disease Association</article-title><source>Int J Mol Sci</source><year>2019</year><volume>20</volume><pub-id pub-id-type="pmcid">PMC6862560</pub-id><pub-id pub-id-type="pmid">31690066</pub-id><pub-id pub-id-type="doi">10.3390/ijms20215496</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharpe</surname><given-names>HR</given-names></name><name><surname>Bowyer</surname><given-names>G</given-names></name><name><surname>Brackenridge</surname><given-names>S</given-names></name><etal/></person-group><article-title>HLA-E: exploiting pathogen-host interactions for vaccine development</article-title><source>Clin Exp Immunol</source><year>2019</year><volume>196</volume><fpage>167</fpage><lpage>177</lpage><pub-id pub-id-type="pmcid">PMC6468186</pub-id><pub-id pub-id-type="pmid">30968409</pub-id><pub-id pub-id-type="doi">10.1111/cei.13292</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Contini</surname><given-names>P</given-names></name><name><surname>Murdaca</surname><given-names>G</given-names></name><name><surname>Puppo</surname><given-names>F</given-names></name><etal/></person-group><article-title>HLA-G Expressing Immune Cells in Immune Mediated Diseases</article-title><source>Front Immunol</source><year>2020</year><volume>11</volume><elocation-id>1613</elocation-id><pub-id pub-id-type="pmcid">PMC7484697</pub-id><pub-id pub-id-type="pmid">32983083</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.01613</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morandi</surname><given-names>F</given-names></name><name><surname>Rizzo</surname><given-names>R</given-names></name><name><surname>Fainardi</surname><given-names>E</given-names></name><etal/></person-group><article-title>Recent Advances in Our Understanding of HLA-G Biology: Lessons from a Wide Spectrum of Human Diseases</article-title><source>J Immunol Res</source><year>2016</year><volume>2016</volume><elocation-id>4326495</elocation-id><pub-id pub-id-type="pmcid">PMC5019910</pub-id><pub-id pub-id-type="pmid">27652273</pub-id><pub-id pub-id-type="doi">10.1155/2016/4326495</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anna</surname><given-names>F</given-names></name><name><surname>Bole-Richard</surname><given-names>E</given-names></name><name><surname>LeMaoult</surname><given-names>J</given-names></name><etal/></person-group><article-title>First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G</article-title><source>J Immunother Cancer</source><year>2021</year><volume>9</volume><pub-id pub-id-type="pmcid">PMC7978334</pub-id><pub-id pub-id-type="pmid">33737343</pub-id><pub-id pub-id-type="doi">10.1136/jitc-2020-001998</pub-id></element-citation></ref></ref-list></back><floats-group><boxed-text id="BX1" position="float" orientation="portrait"><caption><title>Key Points</title></caption><list list-type="bullet" id="L3"><list-item><p>Non-classical HLAs play immunomodulatory roles in the immune system.</p></list-item><list-item><p>HLA-E restricted T-cell therapy may reduce COVID-19 associated cytokine storm.</p></list-item><list-item><p>In silico models developed for predicting binders for HLA-G and HLA-E.</p></list-item><list-item><p>Identification of non-classical HLA binders in strains of coronavirus</p></list-item><list-item><p>A webserver for predicting promiscuous binders for non-classical HLA alleles</p></list-item></list></boxed-text><fig id="F1" position="float"><label>Figure 1</label><caption><p>Schematic representation of non-classical HLAs (HLA-G and HLA-E) with immunomodulatory functions (inhibition/activation effects) when interact with the effective immune cells</p></caption><graphic xlink:href="EMS161000-f001"/></fig><fig id="F2" position="float"><label>Figure 2</label><caption><p>The average amino acid composition of HLA-G*01:01, -G*01:03, -G*01:04, -E*01:01, and -E*01:03 binding/non-binding peptides</p></caption><graphic xlink:href="EMS161000-f002"/></fig><fig id="F3" position="float"><label>Figure 3</label><caption><p>Positional abundance of amino-acid residues in HLA-G*01:01, -G*01:03, -G*01:04, -E*01:01, - E*01:03 binding/non-binding or (positive/negative) peptides, by TSL plots</p></caption><graphic xlink:href="EMS161000-f003"/></fig><fig id="F4" position="float"><label>Figure 4</label><caption><p><bold>Usage of predict and scan module of HLA<sub>nc</sub>Pred</bold> The ‘HLA<sub>nc</sub>Pred’ web-server is compatible with a number of devices (iPhone, iPad, laptops, android mobile phones, etc.) and was build using HTML, PHP and JAVA scripts.</p></caption><graphic xlink:href="EMS161000-f004"/></fig><fig id="F5" position="float"><label>Figure 4</label><caption><p>Complete architecture of HLA<sub>nc</sub>Pred including the dataset collection, feature generation, models and tool development</p></caption><graphic xlink:href="EMS161000-f005"/></fig><table-wrap id="T1" position="float" orientation="portrait"><label>Table 1</label><caption><title>Distribution of positive and negative peptides for HLA-G and HLA-E alleles obtained from IEDB and Swiss-Prot database</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle"><italic>HLA</italic></th><th align="center" valign="middle"><italic>HLA-allele</italic></th><th align="center" valign="middle"><italic>Binding Peptides (Positive Dataset)</italic></th><th align="center" valign="middle"><italic>Non-Binding Peptides (Negative Dataset)</italic></th><th align="center" valign="middle"><italic>Total Peptides</italic></th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="3"><italic><bold>HLA-G</bold></italic></td><td align="left" valign="middle">HLA-G*01:01</td><td align="right" valign="middle"><italic>2633</italic></td><td align="right" valign="middle"><italic>2633</italic></td><td align="right" valign="middle"><italic>5266</italic></td></tr><tr><td align="left" valign="middle">HLA-G*01:03</td><td align="right" valign="middle"><italic>751</italic></td><td align="right" valign="middle"><italic>751</italic></td><td align="right" valign="middle"><italic>1502</italic></td></tr><tr><td align="left" valign="middle">HLA-G*01:03</td><td align="right" valign="middle"><italic>812</italic></td><td align="right" valign="middle"><italic>812</italic></td><td align="right" valign="middle"><italic>1624</italic></td></tr><tr><td align="left" valign="middle" rowspan="3"><bold><italic>HLA-E</italic></bold></td><td align="left" valign="middle">HLA-E*01:01</td><td align="right" valign="middle"><italic>142</italic></td><td align="right" valign="middle"><italic>142</italic></td><td align="right" valign="middle"><italic>284</italic></td></tr><tr><td align="left" valign="middle">HLA-E*01:03</td><td align="right" valign="middle"><italic>723</italic></td><td align="right" valign="middle"><italic>723</italic></td><td align="right" valign="middle"><italic>1446</italic></td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="portrait"><label>Table 2</label><caption><title>The performance of machine leaning models developed using AA<sub>15</sub> binary profile-based features of HLA-G alleles on training and validation datasets.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="5">Classifier</th><th align="center" valign="middle" colspan="5">Training Dataset</th><th align="center" valign="middle" colspan="5">Validation Dataset</th></tr><tr><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">AUC</th><th align="center" valign="middle">MCC</th><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">AUC</th><th align="center" valign="middle">MCC</th></tr></thead><tbody><tr><td align="center" valign="middle" colspan="11"><bold>HLA-G*01:01</bold></td></tr><tr><td align="left" valign="middle"><bold>DT</bold></td><td align="right" valign="middle">88.65</td><td align="right" valign="middle">88.03</td><td align="right" valign="middle">88.34</td><td align="right" valign="middle">0.93</td><td align="right" valign="middle">0.77</td><td align="right" valign="middle">89.37</td><td align="right" valign="middle">89.75</td><td align="right" valign="middle">89.56</td><td align="right" valign="middle">0.94</td><td align="right" valign="middle">0.79</td></tr><tr><td align="left" valign="middle"><bold>RF</bold></td><td align="right" valign="middle">95.25</td><td align="right" valign="middle">95.11</td><td align="right" valign="middle">95.18</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.90</td><td align="right" valign="middle">93.93</td><td align="right" valign="middle">95.83</td><td align="right" valign="middle">94.88</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.90</td></tr><tr><td align="left" valign="middle"><bold>LR</bold></td><td align="right" valign="middle">94.26</td><td align="right" valign="middle">94.40</td><td align="right" valign="middle">94.33</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.89</td><td align="right" valign="middle">92.79</td><td align="right" valign="middle">95.07</td><td align="right" valign="middle">93.93</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.88</td></tr><tr><td align="left" valign="middle"><bold>XGB</bold></td><td align="right" valign="middle">95.44</td><td align="right" valign="middle">95.39</td><td align="right" valign="middle">95.42</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.91</td><td align="right" valign="middle">94.12</td><td align="right" valign="middle">92.98</td><td align="right" valign="middle">93.55</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.87</td></tr><tr><td align="left" valign="middle"><bold>KNN</bold></td><td align="right" valign="middle">92.93</td><td align="right" valign="middle">92.83</td><td align="right" valign="middle">92.88</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">91.27</td><td align="right" valign="middle">94.12</td><td align="right" valign="middle">92.69</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.85</td></tr><tr><td align="left" valign="middle"><bold>GBM</bold></td><td align="right" valign="middle">93.31</td><td align="right" valign="middle">79.77</td><td align="right" valign="middle">86.54</td><td align="right" valign="middle">0.87</td><td align="right" valign="middle">0.74</td><td align="right" valign="middle">91.08</td><td align="right" valign="middle">86.34</td><td align="right" valign="middle">88.71</td><td align="right" valign="middle">0.90</td><td align="right" valign="middle">0.78</td></tr><tr><td align="left" valign="middle"><bold>ET</bold></td><td align="right" valign="middle">95.39</td><td align="right" valign="middle">95.39</td><td align="right" valign="middle">95.39</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.91</td><td align="right" valign="middle">93.93</td><td align="right" valign="middle">96.02</td><td align="right" valign="middle">94.97</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.90</td></tr><tr><td align="left" valign="middle"><bold>SVC</bold></td><td align="right" valign="middle">95.30</td><td align="right" valign="middle">95.58</td><td align="right" valign="middle">95.44</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.91</td><td align="right" valign="middle">94.50</td><td align="right" valign="middle">95.83</td><td align="right" valign="middle">95.16</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.90</td></tr><tr><td align="center" valign="middle" colspan="11"><bold>HLA-G*01:03</bold></td></tr><tr><td align="left" valign="middle"><bold>DT</bold></td><td align="right" valign="middle">82.36</td><td align="right" valign="middle">84.67</td><td align="right" valign="middle">83.51</td><td align="right" valign="middle">0.89</td><td align="right" valign="middle">0.67</td><td align="right" valign="middle">80.67</td><td align="right" valign="middle">82.78</td><td align="right" valign="middle">81.73</td><td align="right" valign="middle">0.88</td><td align="right" valign="middle">0.64</td></tr><tr><td align="left" valign="middle"><bold>RF</bold></td><td align="right" valign="middle">92.18</td><td align="right" valign="middle">92.33</td><td align="right" valign="middle">92.26</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.85</td><td align="right" valign="middle">87.33</td><td align="right" valign="middle">94.04</td><td align="right" valign="middle">90.70</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.82</td></tr><tr><td align="left" valign="middle"><bold>LR</bold></td><td align="right" valign="middle">91.51</td><td align="right" valign="middle">91.67</td><td align="right" valign="middle">91.59</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.83</td><td align="right" valign="middle">88.00</td><td align="right" valign="middle">94.70</td><td align="right" valign="middle">91.36</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.83</td></tr><tr><td align="left" valign="middle"><bold>XGB</bold></td><td align="right" valign="middle">92.18</td><td align="right" valign="middle">92.33</td><td align="right" valign="middle">92.26</td><td align="right" valign="middle">0.99</td><td align="right" valign="middle">0.85</td><td align="right" valign="middle">90.00</td><td align="right" valign="middle">93.38</td><td align="right" valign="middle">91.69</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.83</td></tr><tr><td align="left" valign="middle"><bold>KNN</bold></td><td align="right" valign="middle">89.35</td><td align="right" valign="middle">88.83</td><td align="right" valign="middle">89.09</td><td align="right" valign="middle">0.95</td><td align="right" valign="middle">0.78</td><td align="right" valign="middle">85.33</td><td align="right" valign="middle">95.36</td><td align="right" valign="middle">90.37</td><td align="right" valign="middle">0.94</td><td align="right" valign="middle">0.81</td></tr><tr><td align="left" valign="middle"><bold>GBM</bold></td><td align="right" valign="middle">93.84</td><td align="right" valign="middle">57.83</td><td align="right" valign="middle">75.85</td><td align="right" valign="middle">0.76</td><td align="right" valign="middle">0.55</td><td align="right" valign="middle">91.33</td><td align="right" valign="middle">65.56</td><td align="right" valign="middle">78.41</td><td align="right" valign="middle">0.78</td><td align="right" valign="middle">0.59</td></tr><tr><td align="left" valign="middle"><bold>ET</bold></td><td align="right" valign="middle">92.85</td><td align="right" valign="middle">92.67</td><td align="right" valign="middle">92.76</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">89.33</td><td align="right" valign="middle">94.04</td><td align="right" valign="middle">91.69</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.84</td></tr><tr><td align="left" valign="middle"><bold>SVC</bold></td><td align="right" valign="middle">92.35</td><td align="right" valign="middle">92.50</td><td align="right" valign="middle">92.42</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.85</td><td align="right" valign="middle">88.00</td><td align="right" valign="middle">95.36</td><td align="right" valign="middle">91.69</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.84</td></tr><tr><td align="center" valign="middle" colspan="11"><bold>HLA-G*01:04</bold></td></tr><tr><td align="left" valign="middle"><bold>DT</bold></td><td align="right" valign="middle">79.54</td><td align="right" valign="middle">80.74</td><td align="right" valign="middle">80.14</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">0.60</td><td align="right" valign="middle">86.42</td><td align="right" valign="middle">76.69</td><td align="right" valign="middle">81.54</td><td align="right" valign="middle">0.87</td><td align="right" valign="middle">0.63</td></tr><tr><td align="left" valign="middle"><bold>RF</bold></td><td align="right" valign="middle">93.08</td><td align="right" valign="middle">93.07</td><td align="right" valign="middle">93.07</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">96.30</td><td align="right" valign="middle">93.87</td><td align="right" valign="middle">95.08</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.90</td></tr><tr><td align="left" valign="middle"><bold>LR</bold></td><td align="right" valign="middle">92.31</td><td align="right" valign="middle">92.30</td><td align="right" valign="middle">92.30</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.85</td><td align="right" valign="middle">96.30</td><td align="right" valign="middle">92.64</td><td align="right" valign="middle">94.46</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.89</td></tr><tr><td align="left" valign="middle"><bold>XGB</bold></td><td align="right" valign="middle">92.62</td><td align="right" valign="middle">92.76</td><td align="right" valign="middle">92.69</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.85</td><td align="right" valign="middle">95.06</td><td align="right" valign="middle">94.48</td><td align="right" valign="middle">94.77</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.90</td></tr><tr><td align="left" valign="middle"><bold>KNN</bold></td><td align="right" valign="middle">89.85</td><td align="right" valign="middle">89.99</td><td align="right" valign="middle">89.92</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.80</td><td align="right" valign="middle">95.06</td><td align="right" valign="middle">90.80</td><td align="right" valign="middle">92.92</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.86</td></tr><tr><td align="left" valign="middle"><bold>GBM</bold></td><td align="right" valign="middle">90.77</td><td align="right" valign="middle">67.49</td><td align="right" valign="middle">79.14</td><td align="right" valign="middle">0.79</td><td align="right" valign="middle">0.60</td><td align="right" valign="middle">93.21</td><td align="right" valign="middle">67.49</td><td align="right" valign="middle">80.31</td><td align="right" valign="middle">0.80</td><td align="right" valign="middle">0.63</td></tr><tr><td align="left" valign="middle"><bold>ET</bold></td><td align="right" valign="middle">93.39</td><td align="right" valign="middle">93.22</td><td align="right" valign="middle">93.30</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.87</td><td align="right" valign="middle">96.30</td><td align="right" valign="middle">93.87</td><td align="right" valign="middle">95.08</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.90</td></tr><tr><td align="left" valign="middle"><bold>SVC</bold></td><td align="right" valign="middle">93.08</td><td align="right" valign="middle">93.07</td><td align="right" valign="middle">93.07</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">96.91</td><td align="right" valign="middle">93.87</td><td align="right" valign="middle">95.39</td><td align="right" valign="middle">0.98</td><td align="right" valign="middle">0.91</td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><p id="P38">DT; Decision Tree, RF; Random Forest, LR; Logistic Regression, XGB; XGBoost, KNN; k-nearest neighbors, GNB; Gaussian Naive Bayes, ET; ExtraTree, SVC; Support Vector Classifier; AUC; Area Under Receiver Operating Curve, MCC; Matthews correlation coefficient.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3</label><caption><title>The performance of machine leaning models developed using AA<sub>15</sub> binary profile-based features of HLA-E alleles on training and validation datasets.</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="3">Classifier</th><th align="center" valign="middle" colspan="5">Training Dataset</th><th align="center" valign="middle" colspan="5">Validation Dataset</th></tr><tr><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">AUC</th><th align="center" valign="middle">MCC</th><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">AUC</th><th align="center" valign="middle">MCC</th></tr></thead><tbody><tr><td align="center" valign="middle" colspan="11"><bold>HLA-E*01:01</bold></td></tr><tr><td align="left" valign="middle"><bold>DT</bold></td><td align="right" valign="middle">78.07</td><td align="right" valign="middle">76.99</td><td align="right" valign="middle">77.53</td><td align="right" valign="middle">0.82</td><td align="right" valign="middle">0.55</td><td align="right" valign="middle">75.00</td><td align="right" valign="middle">75.86</td><td align="right" valign="middle">75.44</td><td align="right" valign="middle">0.81</td><td align="right" valign="middle">0.51</td></tr><tr><td align="left" valign="middle"><bold>RF</bold></td><td align="right" valign="middle">86.84</td><td align="right" valign="middle">86.73</td><td align="right" valign="middle">86.78</td><td align="right" valign="middle">0.95</td><td align="right" valign="middle">0.74</td><td align="right" valign="middle">89.29</td><td align="right" valign="middle">86.21</td><td align="right" valign="middle">87.72</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.76</td></tr><tr><td align="left" valign="middle"><bold>LR</bold></td><td align="right" valign="middle">88.60</td><td align="right" valign="middle">89.38</td><td align="right" valign="middle">88.99</td><td align="right" valign="middle">0.94</td><td align="right" valign="middle">0.78</td><td align="right" valign="middle">85.71</td><td align="right" valign="middle">89.66</td><td align="right" valign="middle">87.72</td><td align="right" valign="middle">0.97</td><td align="right" valign="middle">0.76</td></tr><tr><td align="left" valign="middle"><bold>XGB</bold></td><td align="right" valign="middle">86.84</td><td align="right" valign="middle">86.73</td><td align="right" valign="middle">86.78</td><td align="right" valign="middle">0.95</td><td align="right" valign="middle">0.74</td><td align="right" valign="middle">89.29</td><td align="right" valign="middle">86.21</td><td align="right" valign="middle">87.72</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.76</td></tr><tr><td align="left" valign="middle"><bold>KNN</bold></td><td align="right" valign="middle">83.33</td><td align="right" valign="middle">83.19</td><td align="right" valign="middle">83.26</td><td align="right" valign="middle">0.91</td><td align="right" valign="middle">0.67</td><td align="right" valign="middle">82.14</td><td align="right" valign="middle">82.76</td><td align="right" valign="middle">82.46</td><td align="right" valign="middle">0.93</td><td align="right" valign="middle">0.65</td></tr><tr><td align="left" valign="middle"><bold>GBM</bold></td><td align="right" valign="middle">74.56</td><td align="right" valign="middle">76.99</td><td align="right" valign="middle">75.77</td><td align="right" valign="middle">0.76</td><td align="right" valign="middle">0.52</td><td align="right" valign="middle">89.29</td><td align="right" valign="middle">79.31</td><td align="right" valign="middle">84.21</td><td align="right" valign="middle">0.84</td><td align="right" valign="middle">0.69</td></tr><tr><td align="left" valign="middle"><bold>ET</bold></td><td align="right" valign="middle">87.72</td><td align="right" valign="middle">87.61</td><td align="right" valign="middle">87.67</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.75</td><td align="right" valign="middle">92.86</td><td align="right" valign="middle">86.21</td><td align="right" valign="middle">89.47</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.79</td></tr><tr><td align="left" valign="middle"><bold>SVC</bold></td><td align="right" valign="middle">86.84</td><td align="right" valign="middle">86.73</td><td align="right" valign="middle">86.78</td><td align="right" valign="middle">0.94</td><td align="right" valign="middle">0.74</td><td align="right" valign="middle">85.71</td><td align="right" valign="middle">86.21</td><td align="right" valign="middle">85.97</td><td align="right" valign="middle">0.96</td><td align="right" valign="middle">0.72</td></tr><tr><td align="center" valign="middle" colspan="11"><bold>HLA-E*01:03</bold></td></tr><tr><td align="left" valign="middle"><bold>DT</bold></td><td align="right" valign="middle">74.39</td><td align="right" valign="middle">75.09</td><td align="right" valign="middle">74.74</td><td align="right" valign="middle">0.79</td><td align="right" valign="middle">0.50</td><td align="right" valign="middle">72.41</td><td align="right" valign="middle">73.10</td><td align="right" valign="middle">72.76</td><td align="right" valign="middle">0.77</td><td align="right" valign="middle">0.46</td></tr><tr><td align="left" valign="middle"><bold>RF</bold></td><td align="right" valign="middle">84.95</td><td align="right" valign="middle">84.60</td><td align="right" valign="middle">84.78</td><td align="right" valign="middle">0.93</td><td align="right" valign="middle">0.70</td><td align="right" valign="middle">82.07</td><td align="right" valign="middle">83.45</td><td align="right" valign="middle">82.76</td><td align="right" valign="middle">0.88</td><td align="right" valign="middle">0.66</td></tr><tr><td align="left" valign="middle"><bold>LR</bold></td><td align="right" valign="middle">84.78</td><td align="right" valign="middle">84.78</td><td align="right" valign="middle">84.78</td><td align="right" valign="middle">0.92</td><td align="right" valign="middle">0.70</td><td align="right" valign="middle">79.31</td><td align="right" valign="middle">82.07</td><td align="right" valign="middle">80.69</td><td align="right" valign="middle">0.88</td><td align="right" valign="middle">0.61</td></tr><tr><td align="left" valign="middle"><bold>XGB</bold></td><td align="right" valign="middle">85.64</td><td align="right" valign="middle">85.12</td><td align="right" valign="middle">85.38</td><td align="right" valign="middle">0.92</td><td align="right" valign="middle">0.71</td><td align="right" valign="middle">77.24</td><td align="right" valign="middle">78.62</td><td align="right" valign="middle">77.93</td><td align="right" valign="middle">0.87</td><td align="right" valign="middle">0.56</td></tr><tr><td align="left" valign="middle"><bold>KNN</bold></td><td align="right" valign="middle">82.53</td><td align="right" valign="middle">83.56</td><td align="right" valign="middle">83.05</td><td align="right" valign="middle">0.91</td><td align="right" valign="middle">0.66</td><td align="right" valign="middle">78.62</td><td align="right" valign="middle">80.00</td><td align="right" valign="middle">79.31</td><td align="right" valign="middle">0.86</td><td align="right" valign="middle">0.59</td></tr><tr><td align="left" valign="middle"><bold>GBM</bold></td><td align="right" valign="middle">93.43</td><td align="right" valign="middle">30.97</td><td align="right" valign="middle">62.20</td><td align="right" valign="middle">0.62</td><td align="right" valign="middle">0.31</td><td align="right" valign="middle">93.10</td><td align="right" valign="middle">29.66</td><td align="right" valign="middle">61.38</td><td align="right" valign="middle">0.61</td><td align="right" valign="middle">0.29</td></tr><tr><td align="left" valign="middle"><bold>ET</bold></td><td align="right" valign="middle">84.78</td><td align="right" valign="middle">84.60</td><td align="right" valign="middle">84.69</td><td align="right" valign="middle">0.93</td><td align="right" valign="middle">0.69</td><td align="right" valign="middle">80.00</td><td align="right" valign="middle">84.14</td><td align="right" valign="middle">82.07</td><td align="right" valign="middle">0.89</td><td align="right" valign="middle">0.64</td></tr><tr><td align="left" valign="middle"><bold>SVC</bold></td><td align="right" valign="middle">85.12</td><td align="right" valign="middle">84.95</td><td align="right" valign="middle">85.04</td><td align="right" valign="middle">0.93</td><td align="right" valign="middle">0.70</td><td align="right" valign="middle">79.31</td><td align="right" valign="middle">76.55</td><td align="right" valign="middle">77.93</td><td align="right" valign="middle">0.89</td><td align="right" valign="middle">0.56</td></tr></tbody></table><table-wrap-foot><fn id="TFN2"><p id="P39">DT; Decision Tree, RF; Random Forest, LR; Logistic Regression, XGB; XGBoost, KNN; k-nearest neighbors, GNB; Gaussian Naive Bayes, ET; ExtraTree, SVC; Support Vector Classifier; AUC; Area Under Receiver Operating Curve, MCC; Matthews correlation coefficient.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T4" position="float" orientation="portrait"><label>Table 4</label><caption><title>Comparison of performance of HLA<sub>nc</sub>Pred and other methods on the updated IEDB dataset</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="2">HLA-Allele</th><th align="center" valign="middle" colspan="3">HLA<sub>nc</sub>Pred</th><th align="center" valign="middle" colspan="3">MHCflurry 2.0</th><th align="center" valign="middle" colspan="3">NetMHCpan 4.1</th></tr><tr><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th><th align="center" valign="middle">Sensitivity</th><th align="center" valign="middle">Specificity</th><th align="center" valign="middle">Accuracy</th></tr></thead><tbody><tr><td align="left" valign="middle"><bold>HLA-G*01:01</bold></td><td align="right" valign="middle">0.926</td><td align="right" valign="middle">0.943</td><td align="right" valign="middle">0.934</td><td align="right" valign="middle">0.887</td><td align="right" valign="middle">0.933</td><td align="right" valign="middle">0.910</td><td align="right" valign="middle">0.472</td><td align="right" valign="middle">0.987</td><td align="right" valign="middle">0.729</td></tr><tr><td align="left" valign="middle"><bold>HLA-G*01:03</bold></td><td align="right" valign="middle">0.722</td><td align="right" valign="middle">0.611</td><td align="right" valign="middle">0.667</td><td align="right" valign="middle">0.278</td><td align="right" valign="middle">0.944</td><td align="right" valign="middle">0.611</td><td align="right" valign="middle">0.083</td><td align="right" valign="middle">0.972</td><td align="right" valign="middle">0.528</td></tr><tr><td align="left" valign="middle"><bold>HLA-G*01:04</bold></td><td align="right" valign="middle">0.735</td><td align="right" valign="middle">0.706</td><td align="right" valign="middle">0.721</td><td align="right" valign="middle">0.324</td><td align="right" valign="middle">0.971</td><td align="right" valign="middle">0.647</td><td align="right" valign="middle">0.118</td><td align="right" valign="middle">1.000</td><td align="right" valign="middle">0.559</td></tr></tbody></table></table-wrap><table-wrap id="T5" position="float" orientation="portrait"><label>Table 5</label><caption><title>Alterations in the binding sites of non-classical HLA alleles by mutations in Spike protein of SARS-CoV-2 variant B.1.1.529 (Omicron).</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="2"><italic>Alleles</italic></th><th align="center" valign="middle" rowspan="2"><italic>Mutation</italic></th><th align="center" valign="middle" rowspan="2"><italic>Reference Peptide</italic></th><th align="center" valign="middle" rowspan="2"><italic>Mutated Peptide</italic></th><th align="center" valign="middle" colspan="2"><italic>Prediction (Binder/Non-binder)</italic></th></tr><tr><th align="center" valign="middle"><italic>(Reference)</italic></th><th align="center" valign="middle"><italic>(Mutated)</italic></th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="3"><bold>HLA-G*01:01</bold></td><td align="left" valign="middle"><bold>Δ 211, L212I</bold></td><td align="left" valign="middle">DLPQGFSAL</td><td align="left" valign="middle">DPIGEPESA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>S371L</bold></td><td align="left" valign="middle">VLYNSASFS</td><td align="left" valign="middle">VLYNSASFL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>P681H</bold></td><td align="left" valign="middle">PSVASQSII</td><td align="left" valign="middle">HSVASQSII</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle" rowspan="5"><bold>HLA-G*01:03</bold></td><td align="left" valign="middle"><bold>Δ 211, L212I</bold></td><td align="left" valign="middle">DLPQGFSAL</td><td align="left" valign="middle">DPIGEPESA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>S371L</bold></td><td align="left" valign="middle">VLYNSASFS</td><td align="left" valign="middle">VLYNSASFL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>D614G</bold></td><td align="left" valign="middle">DEVPVAIHA</td><td align="left" valign="middle">GEVPVAIHA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>Q954H</bold></td><td align="left" valign="middle">QNAQQLNTL</td><td align="left" valign="middle">QNAQHLNTL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>N969K</bold></td><td align="left" valign="middle">NSSVLNDIL</td><td align="left" valign="middle">KSSVLNDIL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle" rowspan="6"><bold>HLA-G*01:04</bold></td><td align="left" valign="middle"><bold>Δ 211, L212I</bold></td><td align="left" valign="middle">DLPQGFSAL</td><td align="left" valign="middle">DPIGEPESA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>G339D</bold></td><td align="left" valign="middle">LCPFGEVFG</td><td align="left" valign="middle">LCPFGEVFD</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>T547K</bold></td><td align="left" valign="middle">TLTESNKKF</td><td align="left" valign="middle">KLTESNKKF</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>N679K</bold></td><td align="left" valign="middle">NSPRNARSV</td><td align="left" valign="middle">NSPRKAHSV</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>Q954H</bold></td><td align="left" valign="middle">QNAQQLNTL</td><td align="left" valign="middle">QNAQHLNTL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>N969K</bold></td><td align="left" valign="middle">NSSVLNDIL</td><td align="left" valign="middle">KSSVLNDIL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle" rowspan="3"><bold>HLA-E*01:01</bold></td><td align="left" valign="middle"><bold>Δ 211, L212I</bold></td><td align="left" valign="middle">DLPQGFSAL</td><td align="left" valign="middle">DPIGEPESA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>S371L</bold></td><td align="left" valign="middle">VLYNSASFS</td><td align="left" valign="middle">VLYNSASFL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>T547K</bold></td><td align="left" valign="middle">NGLTGTGTL</td><td align="left" valign="middle">NGLTGTGKL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle" rowspan="8"><bold>HLA-E*01:03</bold></td><td align="left" valign="middle"><bold>A67V, Del 69</bold></td><td align="left" valign="middle">NVTWFHAIH</td><td align="left" valign="middle">NVTWFHVIV</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>Δ 211, L212I</bold></td><td align="left" valign="middle">DLPQGFSAL</td><td align="left" valign="middle">DPIGEPESA</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>G339D</bold></td><td align="left" valign="middle">LCPFGEVFG</td><td align="left" valign="middle">LCPFGEVFD</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>S371L</bold></td><td align="left" valign="middle">VLYNSASFS</td><td align="left" valign="middle">VLYNSASFL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>S371L, S373P, S375F</bold></td><td align="left" valign="middle">FSTSKSYGV</td><td align="left" valign="middle">FLTPKFYGV</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>T547K</bold></td><td align="left" valign="middle">GLTGTGTLT</td><td align="left" valign="middle">GLTGTGKLT</td><td align="left" valign="middle">Binder</td><td align="left" valign="middle">Non-binder</td></tr><tr><td align="left" valign="middle"><bold>N679K</bold></td><td align="left" valign="middle">NSPRNARSV</td><td align="left" valign="middle">NSPRKAHSV</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr><tr><td align="left" valign="middle"><bold>D796Y</bold></td><td align="left" valign="middle">GGDNFSQIL</td><td align="left" valign="middle">GGYNFSQIL</td><td align="left" valign="middle">Non-binder</td><td align="left" valign="middle">Binder</td></tr></tbody></table></table-wrap></floats-group></article>